BBTV

About Us

all episodes

EXAS – Exact Sciences CEO Kevin Conroy Interviewed by Mark Monane

Wall Street on BioBusiness.TV
  1. One of the Most Prevalent and Preventable Cancers Could See a Highly Effective Early Detection Test
  2. ColoGuard: the Science and Medicine Behind the Diagnostic
  3. Getting to Market: Regulatory Pathway, Clinical Trial Design, Timeline, Risk Analysis
  4. Commercialization: from Approval to the Billion Dollar Revenue

VICL – Vical CEO Vijay Samant interviewed by Stephen Willey

Wall Street on BioBusiness.TV
  1. DNA Vaccines, a Fast and Efficient ‘Plug-N-Play’ Technology
  2. Allovectin-7, a Phase 3 Cancer Immunotherapy for Head & Neck Tumors
  3. TransVax, a Phase 2 DNA Vaccine to Prevent Cytomegalovirus (CMV) Reactivation
  4. Vical’s Speed and Adaptability Play on Pandemic Influenza Appeals to Department of Defense for Military Vaccines
  5. Vical Licensors, Sanofi and Angios, in Phase 3 Trials on Multi-Billion Dollar PAD Market

MYGN – Myriad Genetics CEO Peter Meldrum Interviewed by Charles Duncan

Wall Street on BioBusiness.TV
  1. A Brief History of Myriad Genetics
  2. BRAC Analysis, Myriad Genetics’ Primary Revenue Driver
  3. Is a European Expansion to be Expected from Myriad Genetics? Checklist and Roadmap
  4. Optimal Chemotherapy Dosing with OnDose, from Myriad Genetics
  5. Myriad Genetics’ Latest Diagnostic (PROLARIS) Predicts Prostate Cancer Recurrence.
  6. Patenting Genes: What if the ACLU Wins the Case Against Myriad Genetics?
  7. Financials: How is Myriad Genetics Planning to Return Cash to Investors?

Paion AG CEO Wolfgang Soehngen Interviewed by Swati Kumar

Wall Street on BioBusiness.TV
  1. Batman is Back, Busting Clots with Desmotoplase
  2. Paion De-Risks Pipeline with Acquisition of New Value Driver CNS 7056
  3. IPaion’s Search & Develop Strategy: Get the Proof of Concept Faster and Cheaper than Pharma

Addex CEO Vincent Mutel Interviewed by Ram Selvaraju

Wall Street on BioBusiness.TV
  1. Dim That Receptor Activity with Addex’s Allosteric Modulation
  2. Addex’s New Lead Molecule ADX48621, Expected To Be Partnered Soon?
  3. December 2009, A Major Setback for Addex. Use of Cash, and Other Pipeline Molecules
  4. ADDEX Undervalued? What Could Drive Stock Price In The Next 6 Months

AUXL – Auxilium CEO Armando Anido Interviewed by Salveen Kochnover

Wall Street on BioBusiness.TV
  1. XIAFLEX Driving Stock, Dupuytren Indication
  2. The CEO’s Strategy to Bring XIAFLEX to the Dupuytren Market
  3. Collagenese XIAFLEX Could be a Pipeline in a Product, Treat Multiple Indications
  4. Pfizer Deal, Financials, Business Development, and Upcoming Milestones

ISIS – Isis Pharma CEO Stanley Crooke Interviewed by Mark Monane

Wall Street on BioBusiness.TV
  1. Can ISIS Pharma’s Antisense Turn Drug Discovery on its Head?
  2. Genzyme and ISIS Partnership on Lead Product “Mipomersen” for LDL-Cholesterol Reduction
  3. ISIS Pharma’s Development Strategy, Capital Needs, and Upcoming Milestones to Look Out For
  4. ISIS Pharmaceuticals CEO Comments on Valuation, Plays the “Word Association” Game with Mark Monane

GXDX – Genoptics CEO Tina Nova, Interviewed by Adam Feinstein

Wall Street on BioBusiness.TV

Beyond tests, lab service Genoptix provides comprehensive diagnostics, new efficiencies for the healthcare system.

CEPH – Cephalon CEO Frank Baldino, Interviewed by Eric Schmidt

Wall Street on BioBusiness.TV
  1. Cephalon’s Growth Drivers and Promising Market Opportunities for Amrix, Treanda
  2. Cephalon’s Provigil Cash Cow Running Out of Milk, But Growth Continues With New Products, Indications, and Geographical Markets

CoNCERT CEO Roger Tung, Interviewed by Eric Schmidt

Wall Street on BioBusiness.TV
  1. CoNCERT’s Leading Portfolio Asset to step into GSK Paroxetine’s $3Bn Shoes
  2. CoNCERT’s IPO, Partnering Strategies and Full Integration for it’s Deuterium Substitution Platform & Pipeline Assets
  3. CoNCERT’s Deuterium Substitution Platform to Create Better, Faster, Cheaper Drugs
12Next >>

  • Best of the Web

    • Alzheimer's Disease
    • Antibiotic Resistance
    • Cancer Immunotherapy
    • Cell Therapy
    • Hepatitis C
    • LOL
    • Stem Cells
    • - View All -

  • Series

    • The Stem Cell Review
    • Cancer Immunotherapy

  • Shows

    • Biotech in the Money
    • Wall Street On BBTV
    • Science Breakthrough
    • The Jan Buck Show
    • Special Interview
    • Report on Location

  • Corporate Videos

    • 60sec Pitches
    • Investor Presentations
    • Panorama

  • Store

    • Series Sponsorship
    • Corp. Communications
    • DVDs

  • About the Show


    Wall Street Analysts interviewing Biotech CEOs.

  • ABOUT BIOBUSINESS.TV
  • BioBusiness.TV is the first independent Internet TV Network for biotechnology professionals. We create and syndicate video-based industry focused shows and series that range from scientific breakthroughs, to equity analyst insights, as well as C-level executive and investor interviews on strategy, management, policy, marketing, science and more. We strive to enhance the quality and accessibility of industry video programming, and to deliver information biotechnology professionals can rely on to make sound and informed decisions.
  • PARTNERING WITH BIOBUSINESS.TV
  • If you’ve got great video programs and a growing audience, let BioBusiness.TV help you take it to the next level through our Partner Program. You can reach out to us through our ‘contact us’ page.
  • DISCLAIMER
  • Viewers should verify all claims and do their own due diligence before investing in any securities mentioned on BioBusiness.TV.
  • COPYRIGHT © 2011 BIO BUSINESS TV, INC. All Rights Reserved